An autopsy case of EBV-positive CD8+ T cell lymphoma after allogeneic transplantation of peripheral blood stem cells

Main Article Content

Yukiko Shishido-Hara Rinako Iguchi Junya Kuroda

Abstract

An autopsy case of CD8+ T cell lymphoma after allogenic transplantation of peripheral blood stem cells (PBSC) is presented. A 57-year-old man was first diagnosed with diffuse large B cell lymphoma (DLBCL) based on a biopsy of an inguinal lymph node. The disease progressed with poor response to chemotherapy, and pathological diagnosis was reviewed. The revised diagnosis was angioimmunoblastic T-cell lymphoma (AITL) with secondary development of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL). The patient died 114 days post-allogenic hematopoietic stem cell transplantation (allo-HSCT) and an autopsy was performed. EBV-positive CD8+ cells were systematically observed in organs, including the liver, spleen, gastrointestinal tracts, and lungs. Liver injury was also apparent with sinusoidal obstruction syndrome (SOS) / veno-occlusive disease (VOD), causing splenomegaly. Southern blot analysis of peripheral blood cells revealed the presence of monoclonal EBV DNA, indicating monoclonal expansion of EBV-positive CD8+ cells.


The present case uniquely displayed EBV-positive T-cell post-transplant lymphoproliferative disorder (PTLD), with monoclonal expansion of CD8+ cells. Although its pathophysiology is not fully understood, this is a typical and precious case of posttransplant EBV-positive T-cell lymphoma, designated in the upcoming WHO classification of haematolymphoid tumours, 5th edition.

Article Details

How to Cite
SHISHIDO-HARA, Yukiko; IGUCHI, Rinako; KURODA, Junya. An autopsy case of EBV-positive CD8+ T cell lymphoma after allogeneic transplantation of peripheral blood stem cells. Medical Research Archives, [S.l.], v. 12, n. 9, sep. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5719>. Date accessed: 03 oct. 2024. doi: https://doi.org/10.18103/mra.v12i9.5719.
Section
Case Reports

References

1. Al Hamed R, Bazarbachi AH, Mohty M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transplant. Jan 2020;55(1):25-39. doi:10.1038/s41409-019-0548-7
2. Jiang C, Huang J, Shao J, et al. T-Cell Posttransplant Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Systemic Review. Cell Transplant. Jan-Dec 2024;33:9636897241259722. doi:10.1177/09636897241259722
3. Kuno M, Ito A, Maeshima AM, et al. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Int J Hematol. Aug 2020;112(2):193-199. doi:10.1007/s12185-020-02890-1
4. Tiede C, Maecker-Kolhoff B, Klein C, Kreipe H, Hussein K. Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases. Transplantation. Feb 15 2013;95(3):479-88. doi:10.1097/TP.0b013e3182762e07
5. Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. Jan 2023;482(1):227-244. doi:10.1007/s00428-022-03414-4
6. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. Jul 2022;36(7):1720-1748. doi:10.1038/s41375-022-01620-2
7. Morscio J, Tousseyn T. Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders. World J Transplant. Sep 24 2016;6(3):505-16. doi:10.5500/wjt.v6.i3.505
8. Styczynski J, van der Velden W, Fox CP, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. Jul 2016;101(7):803-11. doi:10.3324/haematol.2016.144428
9. Dojcinov SD, Quintanilla-Martinez L. How I Diagnose EBV-Positive B- and T-Cell Lymphoproliferative Disorders. Am J Clin Pathol. Jan 4 2023;159(1):14-33. doi:10.1093/ajcp/aqac105
10. Sugimoto A, Watanabe T, Matsuoka K, et al. Growth Transformation of B Cells by Epstein-Barr Virus Requires IMPDH2 Induction and Nucleolar Hypertrophy. Microbiol Spectr. Aug 17 2023;11(4):e0044023. doi:10.1128/spectrum.00440-23
11. Margolskee E, Jobanputra V, Jain P, et al. Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget. Jun 21 2016;7(25):37636-37648. doi:10.18632/oncotarget.9400
12. Coleman CB, Wohlford EM, Smith NA, et al. Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. J Virol. Feb 2015;89(4):2301-12. doi:10.1128/JVI.03001-14
13. Smith NA, Coleman CB, Gewurz BE, Rochford R. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells. J Virol. May 18 2020;94(11)doi:10.1128/JVI.00428-20
14. Dayton JS, Lindsten T, Thompson CB, Mitchell BS. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol. Feb 1 1994;152(3):984-91.
15. Clerico M, Dogliotti I, Aroldi A, et al. Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options. J Clin Med. Dec 19 2022;11(24)doi:10.3390/jcm11247542